Search
Search Results
-
Clinical proof of concept for anti-FGF2 therapy in exudative age-related macular degeneration (nAMD): phase 2 trials in treatment-naïve and anti-VEGF pretreated patients
Background/ObjectiveIntravitreal injections of anti-vascular endothelial growth factor (VEGF) agents are the first-line treatment for exudative...
-
Safety and tolerability of intravitreal umedaptanib pegol (anti-FGF2) for neovascular age-related macular degeneration (nAMD): a phase 1, open-label study
ObjectiveTo evaluate the efficacy and safety of a single-dose intravitreal umedaptanib pegol (anti-FGF2, investigational new drug) for the treatment...
-
Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME
Management of vitreoretinal disorders (e.g., neovascular age-related macular degeneration [nAMD] and diabetic macular edema [DME]) have assumed the...
-
Two-year outcomes of episcleral brachytherapy adjunct to anti-VEGF therapy for treatment-resistant nAMD
PurposeThis study was designed to demonstrate the safety and feasibility of episcleral brachytherapy (ESB) for the treatment of anti-vascular...
-
Impact of intravitreal injection therapy on contrast sensitivity in patients with nAMD and DME
PurposeThe study aims to evaluate changes in contrast sensitivity (CS) during therapy with intravitreal vascular endothelial growth factor (VEGF)...
-
Baseline characteristics and treatment response predictive of nAMD outcomes with ranibizumab therapy in treatment-naive patients: the RACER subgroup analysis
BackgroundThe Ranibizumab AMD Clinical Efficacy Study (RACER) conducted in treatment-naive adult Taiwanese patients with neovascular age-related...
-
nAMD: optimization of patient care and patient-oriented information with the help of an internet-based survey
PurposeThis survey was conducted to identify factors that influence how patients with neovascular age-related macular degeneration (nAMD) deal with...
-
Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy
BackgroundAge-related macular degeneration (AMD) is a common and chronic eye condition characterized by the presence of progressive degenerative...
-
Real-life-Ergebnisse der Anti-VEGF-Therapie bei nAMD der Partneraugen
PurposeNeovascular age-related macular degeneration (nAMD) often affects both eyes. This study compared real-life outcomes of the first affected eye...
-
Personalized treatment supported by automated quantitative fluid analysis in active neovascular age-related macular degeneration (nAMD)—a phase III, prospective, multicentre, randomized study: design and methods
IntroductionIn neovascular age-related macular degeneration (nAMD) the exact amount of fluid and its location on optical coherence tomography (OCT)...
-
Findings of uncertain significance by optical coherence tomography (OCT) as prognostic factors in neovascular age-related macular degeneration (nAMD) treated with ranibizumab
BackgroundBiomarkers hold great promise for personalized medicine as information gained from diagnostic or progression markers can be used to tailor...
-
Potential for Treatment Interval Extension in Eyes with nAMD Disease Activity Post Loading Phase in HAWK and HARRIER
IntroductionThe HAWK and HARRIER studies evaluated the efficacy and safety of brolucizumab versus aflibercept in treatment-naïve eyes with...
-
Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis
This study aimed to compare efficacy and treatment burden of treat-and-extend (T&E) anti-VEGF against fixed and pro re nata (PRN) regimens for...
-
Comparison of subretinal aflibercept vs ranibizumab vs bevacizumab in the context of PPV, pneumatic displacement with subretinal air and subretinal tPA in naïve submacular haemorrhage secondary to nAMD. “The Submarine Study”
ObjectiveTo compare efficacy and safety profile of subretinal aflibercept, ranibizumab, and bevacizumab in the context of pars plana vitrectomy,...
-
Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD
ObjectivesTo study the effect of repeated retinal thickness fluctuations during the anti-VEGF therapy maintenance phase in neovascular age-related...
-
Angiogenin, FGF-α, and IL-36β have higher expression levels in aqueous humor of nAMD patients in comparison to cataract patients
BackgroundNumerous cytokines have been proven to participate in the pathogenesis of neovascular age-related macular degeneration (nAMD). The present...
-
Die fibrovaskuläre Umwandlung der CNV bei nAMD unter lang andauernder Anti-VEGF-Therapie
BackgroundUnder long-term anti-VEGF therapy neovascular age-related macular degeneration (nAMD) may result in fibrovascular transformation of...
-
Burden of Disease Study of Patients with Neovascular Age-Related Macular Degeneration in Spain
IntroductionNeovascular age-related macular degeneration (nAMD) is a progressive retinal disease that causes severe and irreversible vision loss. The...
-
Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes
PurposeΤo evaluate the evolution of macular atrophy (MA) in patients with neovascular AMD (nAMD), compared with their fellow eyes exhibiting dry AMD...
